Get the Stockscreener App
13.65
5.86%
-0.85
After Hours:
13.79
0.14
+1.03%
Cadrenal Therapeutics Inc stock is traded at $13.65, with a volume of 42,362.
It is down -5.86% in the last 24 hours and up +79.25% over the past month.
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.
See More
Previous Close:
$14.50
Open:
$14.36
24h Volume:
42,362
Relative Volume:
1.52
Market Cap:
$14.62M
Revenue:
-
Net Income/Loss:
$-4.85M
P/E Ratio:
-19.47
EPS:
-0.7012
Net Cash Flow:
$-3.95M
1W Performance:
+34.09%
1M Performance:
+79.25%
6M Performance:
+49.18%
1Y Performance:
+33.80%
1-Day Range:
$13.65
$14.98
1-Week Range:
$10.21
$15.37
52-Week Range:
$5.40
$32.55
Cadrenal Therapeutics Inc Stock (CVKD) Company Profile
Name
Cadrenal Therapeutics Inc
Sector
Industry
Phone
904-300-0701
Address
822 A1A NORTH, PONTE VEDRA
Cadrenal Therapeutics Inc Stock (CVKD) Latest News
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Sees Significant Increase in Short Interest - MarketBeat
Cadrenal Therapeutics Inc (CVKD-Q) QuotePress Release - The Globe and Mail
Where are the Opportunities in (CVKD) - Stock Traders Daily
Cadrenal Therapeutics Unveils Phase 3 Trials and Market Strategy - TipRanks
Cadrenal Therapeutics to Participate in Lytham Partners Fall 2024 Investor Conference - PR Newswire
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Forecasted to Earn Q3 2024 Earnings of ($2.18) Per Share - MarketBeat
Applied Therapeutics (NASDAQ:APLT) Trading Down 4.1% - Defense World
WATCH LIVE: Fed Chair Jerome Powell speaks after a 50bp interest rate cut - Investing.com
Cancer Biotech Nuvalent’s Stock Jumps on Positive Data - MSN
Cadrenal Therapeutics (CVKD) Stock Rallies In After-Market Trading Ahead Of Regulatory Meeting - Stocks Telegraph
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Short Interest Update - MarketBeat
Eli Lilly invests $1.8B to boost manufacturing footprint in Ireland - MSN
Cadrenal Therapeutics regains Nasdaq compliance - Investing.com India
Cadrenal Therapeutics regains Nasdaq compliance - Investing.com
Cadrenal gears up for FDA talks on heart drug trial - Investing.com India
Cadrenal gears up for FDA talks on heart drug trial - Investing.com
Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD Patients - PR Newswire
Published Findings Highlight Tecarfarin's Potential and Reinforce Need for Better Anticoagulation Therapy in LVAD Patients - PR Newswire
Upcoming Stock Splits This Week (August 19 to August 23) – Stay InvestingTHE BHARAT EXPRESS NEWS - The Bharat Express News
Upcoming Stock Splits This Week (August 19 to August 23) – Stay Invested - MSN
Upcoming Stock Splits This Week (August 19 to August 23) – Stay Invested - Yahoo Finance
Upcoming Stock Splits This Week (August 19 to August 23) – Stay Invested - Nasdaq
Cadrenal announces 1-for-15 reverse stock split By Investing.com - Investing.com Australia
Cadrenal announces 1-for-15 reverse stock split - Investing.com
Cadrenal announces 1-for-15 reverse stock split By Investing.com - Investing.com UK
Cadrenal announces 1-for-15 reverse stock split By Investing.com - Investing.com Canada
Cadrenal Therapeutics Inc: Analyzing CVKD Stock Trends - The InvestChronicle
CVKDCadrenal Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Cadrenal Therapeutics to Present at Upcoming Investor Conferences - Longview News-Journal
Cadrenal Therapeutics to Present at Upcoming Investor Conferences - StockTitan
Cadrenal Therapeutics, Inc. (CVKD): A New Penny Stock to Buy Now - Yahoo Finance
Q3 2024 Earnings Estimate for Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Issued By HC Wainwright - Defense World
10 Best New Penny Stocks To Buy Now - Insider Monkey
CVKD Stock Earnings: Cadrenal Therapeutics Misses EPS for Q2 2024 - InvestorPlace
Cadrenal Therapeutics Provides Second Quarter 2024 Corporate Update - PR Newswire
CVKD: Cadrenal Therapeutics and Abbott Collaborate on Novel Anticoagulant for LVAD Patients - Zacks Small Cap Research
CVKD: Cadrenal Therapeutics and Abbott Collaborate on Novel Anticoagulant for LVAD Patients - Yahoo Finance
Cadrenal Therapeutics Provides Second Quarter 2024 Corporate Update - StockTitan
Cadrenal Therapeutics Inc (CVKD) Stock: Exploring a Year of Highs, Lows, and Trading Volume - The InvestChronicle
CVKD’s price-to-free cash flow ratio: A closer look at its relevance - US Post News
Cadrenal Therapeutics Partners with Abbott on Cardiac Trial - TipRanks
Ponte Vedra-based Cadrenal Therapeutics in talks for partnership with Abbott - Jacksonville Business Journal
Cadrenal Therapeutics and Abbott Initiate Collaborative Effort to Advance Novel Anticoagulant Tecarfarin for Patients with LVADs - PR Newswire
Cadrenal Therapeutics announces stock incentive plan expansion - Investing.com
Cadrenal Therapeutics announces stock incentive plan expansion - Investing.com India
Cadrenal Therapeutics announces stock incentive plan expansion By Investing.com - Investing.com Australia
Cadrenal Therapeutics announces stock incentive plan expansion By Investing.com - Investing.com Nigeria
Cadrenal Therapeutics Enhances Incentives and Adjusts Stock Plan - TipRanks
Cadrenal Therapeutics to Present at the Emerging Growth Conference on July 18, 2024 - Victoria Advocate
Cadrenal Therapeutics to Present at the Emerging Growth Conference on July 18, 2024 - StockTitan
Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now - GlobeNewswire Inc.
Cadrenal Therapeutics Inc Stock (CVKD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):